Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development. 31691159 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Conclusion: Our findings suggest that Bclaf1 affects HCC progression by manipulating c-MYC mRNA stability and that the Hsp90α/Bclaf1/c-Myc axis might be a potential target for therapeutic intervention in HCC. 30015413 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation. 30788663 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Our data also provide a novel mechanistic understanding of GNMT regulation through MYC in the pathogenesis of HCC. 30760754 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Some antigen-expressing <i>MYC;Trp53</i><sup>-/-</sup> HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. 31186238 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE These results suggest that HBx and c-MYC are involved in URI1 expression in HCC-B. 31739577 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Pathway analysis suggested that putative target genes of these essential miRNAs were involved in HCC-associated signaling pathways, such as Wnt, TGF-β, and Ras; whereas protein-protein network (PPI) analysis demonstrated that some validated target genes of these miRNAs, such as PIK3CA, AKT1, MYC, JUN, SMAD4, and SRC, were hub target genes as they have more counts of interacting protein. 31293639 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE Gene Set Enrichment Analysis (GSEA) indicated that primary HCC samples in the TRMT6 high expression group were enriched for the G2M checkpoint, spermatogenesis, and MYC target genes. 31128068 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Since MYC amplification is frequently identified in HCC, co-occurring with EGFR amplification, our findings suggest that targeting EGFR signaling might be essential for JQ1 therapy in advanced HCC. 30770740 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE In an effort to exploit MYC as a therapeutic target, including in hepatocellular carcinoma (HCC), strategies have been developed on the basis of MYC amplification or gene translocation. 30833661 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network. 30382079 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Here, we report that a messenger RNA (mRNA) lipid nanoparticle delivering IL-12 (IL-12-LNP) slows down the progression of MYC oncogene-driven HCC. 30458889 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE In vivo, using liver-specific inducible MYC transgenic mice fed MCD diet, blocking CPT with the pharmacological inhibitor perhexiline decreased apoptosis of intrahepatic CD4<sup>+</sup> T cells and inhibited HCC tumor formation. 29795111 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs. 28869604 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE In this study, we performed systemic delivery of a novel lipid nanoparticle (LNP) encapsulating an anti-miR-17 oligonucleotide in a conditional transgenic mouse model of MYC driven HCC. 29464015 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease CTD_human Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. 29698666 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells. 30007230 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE However, the expression were low compared with those adjacent to HCC area. c-Myc protein was independently predictive of DFS and OS, and it was negatively correlated with tumor size (P = 0.031), tumor number (P = 0.038), and recurrence (P = 0.001). 29690860 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE Finally, MYC is over-expressed in most of HCCs and is a critical regulator of cellular growth, tumor invasion and metastasis. 29507693 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Therefore, we investigated the expression and role of FAM83H in 163 human HCCs and further investigated the relationship between FAM83H and oncogene MYC. 28607447 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Activation of the phosphoinositide 3-kinase-AKT, Yes-associated protein (YAP), and MYC pathways is involved in human liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). 28964793 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 PosttranslationalModification disease BEFREE Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. 28697339 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE Finally, the MYC-positive human hepatocellular carcinoma was characterized by the cytoplasm devoid of lipid accumulation, prominent nucleoli and a higher proliferative activity. 28481866 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 Biomarker disease BEFREE TP53, MYC) with epigenomic or genomic alternations driving poor prognoses of HCC patients. 27006471 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.600 AlteredExpression disease BEFREE TP53-mutated human HCCs revealed increased AURKA expression and a positive correlation between AURKA and MYC expression. 27213815 2016